Company / EPS (Diluted)
Edwards Lifesciences EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$1.83
FY2025
5-year range
$1.83 / $2.44
FY2021-FY2025
Trend
-25.0%
vs FY2024
Sector context
#58 of 159
Health Care
What the data says
At $1.83, Edwards Lifesciences's eps (diluted) ranks #58 of 159 in the Health Care sector. EPS (Diluted) has fluctuated over the past 10 years, ranging from $1.13 in FY2018 to $2.61 in FY2016.
Based on SEC 10-K filings.
1.83 in FY2025 with a 5-year CAGR of +7.1%.
Declined from $2.38 to $1.83 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -9.1%
- 5-Year CAGR
- +7.1%
- 10-Year CAGR
- -
Sector benchmark
#58 of 159 in Health CareTop 36% of 159This company $1.83 Sector average $1.56
▼
+17.6% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 25.0% year-over-year.
- Ranks #58 out of 159 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2016.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.83 | -25.0% |
| FY2024 | $2.44 | +2.5% |
| FY2023 | $2.38 | -2.5% |
| FY2022 | $2.44 | +2.5% |
| FY2021 | $2.38 | +83.1% |
| FY2020 | $1.30 | -20.7% |
| FY2019 | $1.64 | +45.1% |
| FY2018 | $1.13 | -49.8% |
| FY2017 | $2.25 | -13.8% |
| FY2016 | $2.61 | +52.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026